FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172173618> ?p ?o ?g. }

• W2172173618 endingPage "130" @default.
• W2172173618 startingPage "126" @default.
• W2172173618 abstract "Rebeccamycin analog (RA) is an antitumor antibiotic with both topoisomerase I and II inhibiting activity. Topoisomerase inhibitors have demonstrated synergy with platinum agents. We performed a phase I trial of combination RA with oxaliplatin in patients with refractory solid tumors. RA was administered as a 1-hour infusion daily on days 1–5 with oxaliplatin administered on day 5. Cycles were repeated every 21 days. A total of 17 patients were enrolled. The MTD for RA was 80 mg/m2/d for five days along with oxaliplatin 130 mg/m2 on day 5. Myelosuppression was a common occurrence but was mild except in one instance. Dose limiting toxicities included atrial fibrillation and hypophosphatemia. There was evidence of antitumor activity including 3 partial responses in patients with esophageal, gallbladder and hepato-cellular carcinoma; 5 additional patients had stable disease. Thus, the combination of RA and oxaliplatin is both tolerable and has evidence of clinical activity, but given the lack of significant activity for single agent RA across a variety of disease sites, it is unlikely to proceed to phase II development." @default.
• W2172173618 created "2016-06-24" @default.
• W2172173618 creator A5003298368 @default.
• W2172173618 creator A5003353558 @default.
• W2172173618 creator A5004836221 @default.
• W2172173618 creator A5013926915 @default.
• W2172173618 creator A5031011316 @default.
• W2172173618 creator A5036587861 @default.
• W2172173618 creator A5048182458 @default.
• W2172173618 creator A5052538880 @default.
• W2172173618 creator A5060442605 @default.
• W2172173618 creator A5078249826 @default.
• W2172173618 creator A5082948632 @default.
• W2172173618 creator A5084743009 @default.
• W2172173618 date "2009-09-23" @default.
• W2172173618 modified "2023-10-17" @default.
• W2172173618 title "A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors" @default.
• W2172173618 cites W167270335 @default.
• W2172173618 cites W1765276253 @default.
• W2172173618 cites W1989713903 @default.
• W2172173618 cites W1990475913 @default.
• W2172173618 cites W1992177584 @default.
• W2172173618 cites W2005085959 @default.
• W2172173618 cites W2035185002 @default.
• W2172173618 cites W2045714155 @default.
• W2172173618 cites W2068315475 @default.
• W2172173618 cites W2076549897 @default.
• W2172173618 cites W2078725579 @default.
• W2172173618 cites W2113004179 @default.
• W2172173618 cites W2120761260 @default.
• W2172173618 cites W2227844898 @default.
• W2172173618 cites W2099604792 @default.
• W2172173618 doi "https://doi.org/10.1007/s10637-009-9322-9" @default.
• W2172173618 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4199744" @default.
• W2172173618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19774342" @default.
• W2172173618 hasPublicationYear "2009" @default.
• W2172173618 type Work @default.
• W2172173618 sameAs 2172173618 @default.
• W2172173618 citedByCount "17" @default.
• W2172173618 countsByYear W21721736182012 @default.
• W2172173618 countsByYear W21721736182013 @default.
• W2172173618 countsByYear W21721736182014 @default.
• W2172173618 countsByYear W21721736182017 @default.
• W2172173618 countsByYear W21721736182018 @default.
• W2172173618 countsByYear W21721736182019 @default.
• W2172173618 countsByYear W21721736182020 @default.
• W2172173618 countsByYear W21721736182021 @default.
• W2172173618 countsByYear W21721736182022 @default.
• W2172173618 countsByYear W21721736182023 @default.
• W2172173618 crossrefType "journal-article" @default.
• W2172173618 hasAuthorship W2172173618A5003298368 @default.
• W2172173618 hasAuthorship W2172173618A5003353558 @default.
• W2172173618 hasAuthorship W2172173618A5004836221 @default.
• W2172173618 hasAuthorship W2172173618A5013926915 @default.
• W2172173618 hasAuthorship W2172173618A5031011316 @default.
• W2172173618 hasAuthorship W2172173618A5036587861 @default.
• W2172173618 hasAuthorship W2172173618A5048182458 @default.
• W2172173618 hasAuthorship W2172173618A5052538880 @default.
• W2172173618 hasAuthorship W2172173618A5060442605 @default.
• W2172173618 hasAuthorship W2172173618A5078249826 @default.
• W2172173618 hasAuthorship W2172173618A5082948632 @default.
• W2172173618 hasAuthorship W2172173618A5084743009 @default.
• W2172173618 hasBestOaLocation W21721736182 @default.
• W2172173618 hasConcept C121608353 @default.
• W2172173618 hasConcept C126322002 @default.
• W2172173618 hasConcept C142424586 @default.
• W2172173618 hasConcept C147897179 @default.
• W2172173618 hasConcept C185592680 @default.
• W2172173618 hasConcept C202751555 @default.
• W2172173618 hasConcept C2776694085 @default.
• W2172173618 hasConcept C2780962732 @default.
• W2172173618 hasConcept C31760486 @default.
• W2172173618 hasConcept C526805850 @default.
• W2172173618 hasConcept C55493867 @default.
• W2172173618 hasConcept C71924100 @default.
• W2172173618 hasConcept C86803240 @default.
• W2172173618 hasConcept C87355193 @default.
• W2172173618 hasConcept C90924648 @default.
• W2172173618 hasConcept C98274493 @default.
• W2172173618 hasConceptScore W2172173618C121608353 @default.
• W2172173618 hasConceptScore W2172173618C126322002 @default.
• W2172173618 hasConceptScore W2172173618C142424586 @default.
• W2172173618 hasConceptScore W2172173618C147897179 @default.
• W2172173618 hasConceptScore W2172173618C185592680 @default.
• W2172173618 hasConceptScore W2172173618C202751555 @default.
• W2172173618 hasConceptScore W2172173618C2776694085 @default.
• W2172173618 hasConceptScore W2172173618C2780962732 @default.
• W2172173618 hasConceptScore W2172173618C31760486 @default.
• W2172173618 hasConceptScore W2172173618C526805850 @default.
• W2172173618 hasConceptScore W2172173618C55493867 @default.
• W2172173618 hasConceptScore W2172173618C71924100 @default.
• W2172173618 hasConceptScore W2172173618C86803240 @default.
• W2172173618 hasConceptScore W2172173618C87355193 @default.
• W2172173618 hasConceptScore W2172173618C90924648 @default.
• W2172173618 hasConceptScore W2172173618C98274493 @default.
• W2172173618 hasIssue "1" @default.
• W2172173618 hasLocation W21721736181 @default.
• W2172173618 hasLocation W21721736182 @default.

• next